Myung In’s Parkinson’s Tx demonstrates efficacy

By | translator Alice Kang

21.12.17 10:13:51

가나다라 0

Fixed-dose combination of pramipexole·rasagiline shows significant improvement over existing treatment

Plans to release in market 2023 after applying for authorization next year…will be distributed exclusively by Myung In Pharm

A Parkinson’s disease treatment that Myung In Pharm has acquired an exclusive licensing agreement from an Israeli pharmaceutical company - 'P2B001 (Fixed-dose combination of pramipexole+rasagiline)’ – has demonstrated its safety and efficacy at a global Phase III clinical trial.

According to the topline results announced by the Israeli pharmaceutical company Pharma Two B Ltd. (P2B), P2B001 successfully met its primary and key secondary endpoints and demonstrated statistically significant benefit over existing treatments.

A total of 544 patients with early-stage Parkinson's disease in 70 centers in the US, Europe, and Canada were randomized to four treatment arms: P2B001 (pramipex

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)